Recursion Pharmaceuticals (RXRX) Revenue (2020 - 2026)

Recursion Pharmaceuticals (RXRX) has 7 years of Revenue data on file, last reported at $6.5 million in Q1 2026.

• Quarterly Revenue fell 56.11% year-over-year to $6.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $66.4 million (up 11.07% YoY) and the FY2025 annual result came in at $74.7 million, up 26.92% from the prior year.
• Revenue retreated to $6.5 million in Q1 2026, from $35.5 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $35.5 million in Q4 2025 to a low of $4.5 million in Q4 2024.
• A 5-year average of $13.2 million and a median of $12.1 million in 2023 frame the typical range for Revenue.
• The widest YoY moves for Revenue: up 681.74% in 2025, down 80.16% in 2025.
• Tracing RXRX's Revenue over 5 years: stood at $13.7 million in 2022, then retreated by 20.36% to $10.9 million in 2023, then plunged by 58.26% to $4.5 million in 2024, then surged by 681.74% to $35.5 million in 2025, then sank by 81.79% to $6.5 million in 2026.
• The last three Revenue figures came in at $6.5 million (Q1 2026), $35.5 million (Q4 2025), and $5.2 million (Q3 2025), per Business Quant data.